ISB 2001 Shows High Response Rates in Relapsed/Refractory Multiple Myeloma
Ichnos Glenmark Innovation (IGI) presented positive Phase 1 trial data for ISB 2001, a novel trispecific antibody targeting BCMA,...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy manufacturing compliance Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Ichnos Glenmark Innovation (IGI) presented positive Phase 1 trial data for ISB 2001, a novel trispecific antibody targeting BCMA,...
AnaptysBio’s investigational drug, rosnilimab, has shown promising results in a Phase 2b trial for rheumatoid arthritisarthritis (RA). The drug...
Johnson & Johnson’s Phase 3 AMPLITUDE study demonstrates that the combination of niraparib and abiraterone acetate with prednisone significantly...
Tactile Medical presented two-month data from the largest randomized controlled trial on head and neck cancer-related lymphedema at the...
aTyr Pharma released interim Phase 2 data for efzofitimod, a potential treatment for systemic sclerosis-related interstitial lung disease (SSc-ILD)....
Corvus Pharmaceuticals released interim Phase 1 clinical trial data for soquelitinib, an oral ITK inhibitor, in patients with moderate...
Biomerica’s inFoods IBS test, a personalized dietary therapy for Irritable Bowel Syndrome (IBS), demonstrated statistically significant improvement in patient...
Dyne Therapeutics announced preclinical data showing its drug candidate, DYNE-302, improved muscle function in a mouse model of facioscapulohumeral...
Rectify Pharmaceuticals presented data on RTY-822, a positive functional modulator (PFM) targeting the ABCC6 membrane transporter, at the 2025...
In this interview with Dr. Seema Rajsingh, Executive Medical Director and Jarem Edwards, Clinical Scientist – Early Drug Development...